Timolol
- Generic Name
- Timolol
- Brand Names
- Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom
- Drug Type
- Small Molecule
- Chemical Formula
- C13H24N4O3S
- CAS Number
- 26839-75-8
- Unique Ingredient Identifier
- 5JKY92S7BR
- Background
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
- Indication
Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)
PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)
- Conditions
- Primary Open-angle Glaucoma
- Interventions
- Other: Placebo1Drug: Dorzolamide-Timolol OphthalmicOther: Placebo 2Drug: Krytantek
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Laboratorios Sophia S.A de C.V.
- Target Recruit Count
- 51
- Registration Number
- NCT03193333
- Locations
- 🇨🇴
MD. Sandra Belalcazar Rey, Bogotá, Bogotá D.C., Colombia
🇲🇽MD. Victoria Eugenia Sanchez Castellanos, Zapopan, Jalisco, Mexico
Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 2
- Registration Number
- NCT02852057
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study
- Conditions
- Open Angle Glaucoma or Ocular Hypertension
- Interventions
- Drug: DE-117 ophthalmic solution
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 125
- Registration Number
- NCT02822729
Timolol for the Treatment of Acne and Rosacea
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 8
- Registration Number
- NCT02774590
- Locations
- 🇺🇸
Johns Hopkins Dermatology Department, Baltimore, Maryland, United States
Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution
- Conditions
- Glaucoma Open-angle
- Interventions
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 154
- Registration Number
- NCT02754596
- Locations
- 🇺🇸
John Berdahl, MD, Sioux Falls, South Dakota, United States
A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- ForSight Vision5, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT02742649
- Locations
- 🇵🇦
Clinica de Ojos Orillac - Calvo, Panama City, Panama
Topical Timolol for Infantile Hemangioma in Early Proliferative Phase
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Target Recruit Count
- 70
- Registration Number
- NCT02731287
- Locations
- 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸Hospital Virgen del Rocío, Sevilla, Spain
Evaluation of a New Method for Instilling Eye Drops
- Conditions
- Ophthalmic SolutionsGlaucoma
- Interventions
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- University of Waterloo
- Target Recruit Count
- 30
- Registration Number
- NCT02697318
- Locations
- 🇨🇦
University of Waterloo, Waterloo, Ontario, Canada
Timolol Eye Drops in the Treatment of Acute Migraine Headache
- Conditions
- Migraine
- Interventions
- Drug: Artificial tears
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- University of Missouri, Kansas City
- Target Recruit Count
- 10
- Registration Number
- NCT02630719
- Locations
- 🇺🇸
Truman Medical Center, Kansas City, Missouri, United States
Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
- Conditions
- Primary Open-Angle Glaucoma (POAG)Ocular Hypertension (OHT)
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Inotek Pharmaceuticals Corporation
- Target Recruit Count
- 303
- Registration Number
- NCT02565173
- Locations
- 🇺🇸
Inotek Pharmaceuticals Corporation, Lexington, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.